5 things to consider before buying a pet
In Mommy Matters, we have five signs veterinarians say parents should consider before adding a pet to the family.
First, see if your child is comfortable around animals. If they get nervous when they're near a dog or cat, or if they act too roughly with it, they might not be ready for a pet. They also need to respect an animal's space. Getting too close can provoke fear in some pets. Once your child understands that animals have feelings, they're mature enough to be a pet owner.
Kids may be ready for a pet if they can handle completing simple household chores alone. Can they put away laundry or brush their teeth without constant reminders? If they can't, that sets you up for another daily battle to get a child to care for a pet.
Your child is ready for a pet when they are willing to wait and find the right fit for them. For example, if the family is seldom home, a high-energy dog may not be a good choice. A cat that may need less attention may be a better alternative. If the family's gone most of the day, consider a pet that's more active at night, such as a hamster.
Your child should also be mature enough to understand that the decision to get a pet is a family choice. Ask if everyone is ready to pick up the slack if someone doesn't do their part. Make sure everyone knows what they'll be required to do.
And finally, make sure you're ready for the responsibility of a pet, too. If your child doesn't feed or walk the dog, it will fall to you. Make sure you have the time and energy — and the finances — to take care of your pet.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ('Apimeds' or the 'Company'), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company's proprietary ai²™ division. Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division Dr. Kramer brings more than 30 years of experience in biopharmaceutical research and development, including 18 years at Genentech. She most recently served as Executive Vice President of Development at Concentric Analgesics. Mr. Peters, previously Chief Strategy & Insights Officer at Heller Agency, has a proven track record in healthcare innovation, strategic communications, and KOL engagement. In their new roles, Dr. Kramer will oversee all product development activities at Apimeds, while Mr. Peters will lead the strategy, positioning, and launch of the Company's ai²™ platform. 'We're thrilled to welcome Susan and Brian to the Apimeds leadership team,' said Erik Emerson, Chief Executive Officer of Apimeds. 'Strengthening our operational leadership has been a priority since our IPO. Susan enhances our clinical development capabilities at a pivotal time for Apitox, while Brian brings vision, energy, and deep strategic expertise as we build and scale our ai²™ platform.' ' Apitox is an incredibly exciting program,' said Dr. Kramer. 'Having worked with Erik in the past, I know the caliber of his leadership. The scientific potential of purified bee venom and the company's mission made this an easy decision. I'm eager to explore the range of indications where Apitox may bring meaningful therapeutic benefits.' 'Joining Apimeds at this inflection point is an amazing opportunity,' added Mr. Peters. 'The chance to shape and launch ai²™—our internal innovation engine—is compelling in its own right, but combining it with a pipeline as novel as Apitox makes this a truly unique moment.' Dr. Kramer is a co-founder of Corthera, Inc. (acquired by Novartis), and has held senior roles at XOMA, Anesiva, and Annexon Biosciences. She has led global development teams for both biologics and small molecules. She holds a BA from the College of St. Scholastica, an MA in Education from Central Michigan University, and both an MPH and DrPH in Biomedical Sciences (Virology) from the University of California, Berkeley. She has served on numerous boards and scientific advisory committees. Mr. Peters previously served as VP of Sales & Marketing and as a member of the corporate leadership team at Medexus Pharma from 2013 to 2024. Earlier in his career, he held senior leadership positions at Gilead Sciences, Accera, Chiesi, and G.D. Searle. He earned a BA in Communications from Indiana University. About Apimeds Pharmaceuticals US, Inc. Apimeds is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered honeybee venom-based toxin. Apimeds is currently developing Apitox as a potential treatment for osteoarthritis knee pain in patients who fail to respond adequately to conservative non-pharmacologic therapy and common analgesics. For more information, please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated use of the net proceeds from the offering. No assurance can be given that the net proceeds of the Offering will be used as indicated. All statements other than statements of historical facts are forward-looking statements. You can identify these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'likely to' or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy and financial needs. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include forward-looking statements include, but are not limited to, the risks and uncertainties described in 'Special Note Regarding Forward-Looking Statements,' 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and the documents that referred to in the prospectus filed with the SEC with the understanding that the Company's future results may be materially different from and worse than what we expect. Copies are available on the SEC's website, Other sections of the prospectus include additional factors which could adversely impact the Company's business and financial performance. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for the Company's management to predict all risk factors and uncertainties, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company and the underwriters qualify all of the forward-looking statements by these cautionary statements. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the prospectus relate only to events or information as of the date on which the statements are made in the prospectus. Neither the Company nor the underwriters undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read the prospectus and the documents that we refer to in the prospectus and have filed as exhibits to the registration statement, of which the prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect.
Yahoo
3 hours ago
- Yahoo
Hims & Hers Health, Inc. (HIMS) Announces Expansion To Canada
Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and wellness platform announced plans to expand in Canada by offering generic semaglutide. A nurse in a telehealth platform talking with a patient on video call for consultation. This comes at a time when Novo Nordisk is set to lose its patent protection on Ozempic and Wegovy in Canada for not paying a maintenance fee in 2019. Hims & Hers Health, Inc. (NYSE:HIMS) joins a growing list of companies that are capitalizing on Novo Nordisk's lapsed patent on its GLP-1s. The introduction of generics is a pivotal moment for Canada's healthcare industry. With about two-thirds of adults in the country being overweight or obese, access to treatments has remained elusive for many due to the high costs. Hims & Hers Health, Inc. (NYSE:HIMS) intends to offer generic semaglutide at a significant discount to the currently branded versions, with prices expected to further decrease over time. Hims & Hers Health, Inc. (NYSE:HIMS)'s decision to enter the Canadian market follows the company's acquisition of European telehealth platform, Zava, in June, which will expand its services to France, Germany, and Ireland, and grow its active customer base by approximately 50%. While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best German Stocks to Invest in Now and Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
What to Expect From Hologic's Q3 2025 Earnings Report
Marlborough, Massachusetts-based Hologic, Inc. (HOLX) develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health, focusing on early detection and treatment worldwide. With a market cap of $14.4 billion, the company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. HOLX is all geared up for its fiscal Q3 2025 results after the market closes on Wednesday, Jul. 30. Before this event, analysts project this company to report an adjusted EPS of $1.05, down marginally from $1.06 in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in three of the last four quarters, while falling short in one quarter. Palantir Just Launched Warp Speed for Warships. Does That Make PLTR Stock a Buy? This Analyst Just Doubled His Price Target on AMD Stock How High Can Nvidia Stock Go as Jensen Huang Heads to China? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For fiscal 2025, analysts expect HOLX to report an adjusted EPS of $4.19, representing a 2.7% year-over-year increase from $4.08 in fiscal 2024. Moreover, in fiscal 2026, the company's adjusted EPS is expected to increase 7.4% year-over-year to $4.50. HOLX stock has declined 16.8% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 11.6% gain and the Health Care Select Sector SPDR Fund's (XLV) 8.6% decline over the same time frame. On May 1, HOLX stock dropped 1.6% following the release of its Q2 2025 results. The company's revenue declined 1.2% year-over-year, primarily due to a decrease in breast health revenue resulting from lower sales of mammography capital equipment. Moreover, its adjusted EPS for the quarter came in at $1.03, surpassing the consensus estimates marginally. Analysts are moderately optimistic about HOLX's stock, with an overall "Moderate Buy" rating. Among 19 analysts covering the stock, six recommend "Strong Buy," one suggests a 'Moderate Buy,' and 12 advise 'Hold.' The mean price target of $68.67 indicates a 6.3% potential upside from HOLX's current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
